SMS Pharmaceuticals Gestion
Gestion contrôle des critères 2/4
Le PDG SMS Pharmaceuticals est Ramesh Potluri, nommé en Aug1990, a un mandat de 34.25 ans. La rémunération annuelle totale est ₹ 36.88M, composée du salaire de 81.4% et des bonus 18.6%, y compris les actions et options de la société. détient directement 36.22% des actions de la société, d'une valeur de ₹ 7.39B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.5 ans et 2.3 ans.
Informations clés
Ramesh Potluri
Directeur général
₹36.9m
Rémunération totale
| Pourcentage du salaire du PDG | 81.4% |
| Durée du mandat du directeur général | 34.3yrs |
| Propriété du PDG | 36.2% |
| Durée moyenne d'occupation des postes de direction | 5.5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 2.3yrs |
Mises à jour récentes de la gestion
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24
Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23Recent updates
Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%
Nov 14SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹593m |
| Jun 30 2024 | n/a | n/a | ₹570m |
| Mar 31 2024 | ₹37m | ₹30m | ₹498m |
| Dec 31 2023 | n/a | n/a | ₹361m |
| Sep 30 2023 | n/a | n/a | ₹288m |
| Jun 30 2023 | n/a | n/a | ₹150m |
| Mar 31 2023 | ₹31m | ₹30m | -₹71m |
| Dec 31 2022 | n/a | n/a | -₹42m |
| Sep 30 2022 | n/a | n/a | ₹9m |
| Jun 30 2022 | n/a | n/a | ₹259m |
| Mar 31 2022 | ₹38m | ₹26m | ₹622m |
| Dec 31 2021 | n/a | n/a | ₹789m |
| Sep 30 2021 | n/a | n/a | ₹911m |
| Jun 30 2021 | n/a | n/a | ₹791m |
| Mar 31 2021 | ₹47m | ₹21m | ₹625m |
| Dec 31 2020 | n/a | n/a | ₹458m |
| Sep 30 2020 | n/a | n/a | ₹319m |
| Jun 30 2020 | n/a | n/a | ₹308m |
| Mar 31 2020 | ₹26m | ₹20m | ₹316m |
| Dec 31 2019 | n/a | n/a | ₹386m |
| Sep 30 2019 | n/a | n/a | ₹405m |
| Jun 30 2019 | n/a | n/a | ₹406m |
| Mar 31 2019 | ₹32m | ₹20m | ₹400m |
| Mar 31 2018 | ₹32m | ₹20m | ₹317m |
Rémunération vs marché: La rémunération totale de Ramesh ($USD 436.71K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Indian ($USD 194.43K ).
Rémunération et revenus: La rémunération de Ramesh a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Ramesh Potluri (66 yo)
34.3yrs
Titularisation
₹36,875,000
Compensation
Mr. Ramesh Babu Potluri has been the Chairman and Managing Director of SMS Pharmaceuticals Limited since August 30, 1990. Mr. Potluri has pioneered the vision of developing SMS in to one of the leading Pha...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman & MD | 34.3yrs | ₹36.88m | 36.22% ₹ 7.4b | |
| Chief Financial Officer | 7.2yrs | ₹2.37m | pas de données | |
| Company Secretary & Compliance Officer | 2.8yrs | ₹1.53m | pas de données | |
| Executive Director | 3.8yrs | ₹36.83m | 15.74% ₹ 3.2b | |
| Assistant General Manager of HR and Legal | no data | pas de données | pas de données | |
| Head of HRD and General Manager of Purchases | no data | pas de données | pas de données |
5.5yrs
Durée moyenne de l'emploi
61yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de SMSPHARMA est chevronnée et expérimentée (5.5 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman & MD | 34.3yrs | ₹36.88m | 36.22% ₹ 7.4b | |
| Executive Director | 4.4yrs | ₹36.83m | 15.74% ₹ 3.2b | |
| Additional Non-Executive Non-Independent Director | less than a year | pas de données | 2.58% ₹ 527.6m | |
| Non-Executive & Independent Director | 5.3yrs | ₹245.00k | pas de données | |
| Non-Executive & Independent Director | 6.5yrs | ₹590.00k | 0.035% ₹ 7.2m | |
| Additional Non-Executive Independent Director | less than a year | pas de données | pas de données | |
| Non-Executive Non-Independent Director | less than a year | pas de données | pas de données | |
| Non-Executive Independent Director | less than a year | pas de données | pas de données |
2.3yrs
Durée moyenne de l'emploi
62yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la SMSPHARMA n'est pas considéré comme expérimenté ( 2.3 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.